home / stock / vir / vir news


VIR News and Press, Vir Biotechnology Inc. From 04/14/23

Stock Information

Company Name: Vir Biotechnology Inc.
Stock Symbol: VIR
Market: NYSE
Website: vir.bio

Menu

VIR VIR Quote VIR Short VIR News VIR Articles VIR Message Board
Get VIR Alerts

News, Short Squeeze, Breakout and More Instantly...

VIR - IXJ: Healthcare Dashboard For April

2023-04-14 11:28:52 ET Summary Pharmaceuticals/biotechnology is the only subsector with good value and quality scores. Healthcare equipment is the most overvalued one. IXJ: A global alternative to XLV. 10 stocks cheaper than their peers in April. This monthly art...

VIR - Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual...

VIR - U.S. launches $5B program to speed up development of next-gen COVID vaccines

2023-04-10 22:25:44 ET The U.S. government is launching a $5B-plus program to accelerate the development of new coronavirus vaccines and treatments, officials from the Biden administration and the Department of Health and Human Services ( HHS ) confirmed Monday. An HHS official said...

VIR - GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market

2023-04-10 08:26:10 ET Summary GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. Bristol-Myers Squibb's total debt was about $40.8 billion at the end of 2022, down $4.78 billion from the previous year, thanks to the successful integration of Celgene...

VIR - WHO chief expects COVID emergency to end this year

2023-04-06 14:14:11 ET After more than three years, the World Health Organization (WHO) could announce an end to the emergency status of COVID-19 this year, the head of the global body Dr. Tedros Adhanom Ghebreyesus, said Thursday. In early 2020, the WHO named the COVID-19 pandemic a Pu...

VIR - Vectoring In On Vir Biotechnology

2023-03-22 08:51:49 ET Summary Shares of infectious disease medicines concern Vir Biotechnology are trading at only a $6-$7 per share premium to cash as the revenue from its Covid-19 medication dries up. The company has three compounds undergoing evaluation as both monotherapies a...

VIR - Biopharma Exposure In SVB Financial Group And Investor Strategy

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...

VIR - PBE: Healthcare Dashboard For March

2023-03-16 06:31:14 ET Summary The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality. Fast facts on PBE, a biotechnology and genomics ETF. 10 stocks cheape...

VIR - Vir Biotechnology to Participate in the Barclays Global Healthcare Conference

SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, Mar...

VIR - Vir gains as JPMorgan upgrades on flu and Hep B candidates

2023-03-06 07:47:59 ET Vir Biotechnology ( NASDAQ: VIR ) added ~5% pre-market Monday after JPMorgan upgraded the COVID-19 drugmaker citing upcoming data readouts for VIR-2482 and VIR-2218, candidates targeted at influenza A and Hepatitis B Virus, respectively. In mid-202...

Previous 10 Next 10